FDA Approved First New Fibromyalgia Drug in 15 Years
Adults with fibromyalgia have a new non-opioid treatment option following the approval of the daily tablet TONMYA.
Updated on Oct. 7, 2026 in Substance Abuse
Live Poll
Do you feel new FDA-approved treatments are effectively improving options for chronic pain sufferers?
In August 2025, the FDA approved TONMYA, a once-daily sublingual tablet, for the treatment of fibromyalgia. This marks the first new therapy approved for the condition in over 15 years, offering a new path for the estimated 10 million U.S. adults living with the disorder.
Why it matters
The approval provides a new, non-opioid option for managing a condition that has seen few clinical advancements for over a decade. It reflects a shift in treatment availability for the millions of Americans navigating chronic fibromyalgia symptoms.
Clinical evaluation included three Phase 3 trials, with two demonstrating statistically significant pain reduction for patients compared to a placebo. These results grounded the FDA approval process for the medication.
The players
FDA
The United States federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
TONMYA
A newly approved non-opioid, sublingual fibromyalgia medication containing cyclobenzaprine hydrochloride.
The details
TONMYA is formulated with cyclobenzaprine hydrochloride and is designed as a sublingual tablet taken once daily at bedtime. The sublingual delivery method allows for rapid absorption under the tongue, providing a non-opioid approach to symptom management for adults with fibromyalgia.
Timeline
August 2025: The FDA officially approved TONMYA for the treatment of fibromyalgia.
Health Landscape
This approval represents a notable update to the FDA drug approval process for chronic pain management. It fills a significant clinical void that has existed since no new therapies were brought to market for this condition over the last 15 years.
If you are one of the 10 million U.S. adults living with fibromyalgia, this medication is a treatment option worth discussing with your doctor. Consider asking your physician how this non-opioid tablet fits into your current pain management plan and whether it is appropriate for you.
The takeaway
The arrival of a new fibromyalgia treatment is a significant milestone for a condition with limited therapeutic additions. Patients should discuss this new option with their healthcare provider to determine if it suits their specific care needs.
Further reading
For broader context on managing chronic conditions, visit our Substance Abuse section.
More information
Access more details about this therapy via the official medication information portal.
Source note: This article includes information reported by NBC Palm Springs.
Live Poll
Do you feel new FDA-approved treatments are effectively improving options for chronic pain sufferers?
